Skip to content
Companies

Biostax

Low-dose naltrexone for HIV and immune restoration

Raised to date

No sales reported yet

of $7.5M offered across 1 Form D filing

Still open
$7.5M
Investors
20
Last filed
Jun 8, 2026

About

Biostax Corp. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products, with a focus on autoimmunity and immune restoration. Its lead investigational candidate is Lodonal, a once-daily immune system regulator being developed for the management of HIV/AIDS in markets outside the United States. The company also holds JKB-122, a small molecule targeting NASH, autoimmune hepatitis and chronic liver disease, and a BiostaxRx inflammaging program based on low-dose naltrexone formulations. Biostax is publicly quoted on the OTC market under the ticker BTAX and was formerly known as Immune Therapeutics, Inc. before its October 2023 rename.

Biostax focuses on low-dose naltrexone-based immune modulation with a defined path to market in emerging markets — particularly Africa — rather than pursuing a conventional US-first clinical and commercial route.

Funding

  • EquityFiled Jun 8, 2026Form D
    None sold/ $7.5M

Product

Lodonal

Investigational immunotherapeutic drug

A once-a-day immune system regulator, an oral low-dose naltrexone formulation, in development for the management of HIV and AIDS in markets outside the United States.

  • Once-daily oral dosing
  • Low-dose naltrexone immune-modulation mechanism
  • Targeted at HIV/AIDS management in ex-US markets

Built for

Patients and healthcare systems treating HIV/AIDS, chronic liver disease and age-related inflammatory conditions, primarily in emerging markets outside the United States

People on file